Theravance Biopharma Inc. (TBPH)
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
Theravance Q1 earnings top estimates as collaboration revenues grow, while restructuring and cost cuts aim to drive $60-$70M annualized cash flow.
Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Theravance Stock Declines Around 17% in Three Months: Here's Why
TBPH shares sink in three months after its lead drug fails a late-stage study, forcing a pipeline overhaul and raising uncertainty over its future direction.
Here's Why Theravance Biopharma (TBPH) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Theravance's Q4 Earnings and Revenues Miss Estimates
TBPH's posts Q4 earnings miss despite 145% revenue surge; scraps Ampreloxetine, launches restructuring and weighs a potential sale.
All You Need to Know About Theravance Bio (TBPH) Rating Upgrade to Strong Buy
Theravance Bio (TBPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Here's Why Theravance Biopharma (TBPH) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Theravance Biopharma (TBPH) Q4 Earnings and Revenues Lag Estimates
Theravance Biopharma (TBPH) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.44 per share. This compares to a loss of $0.05 per share a year ago.
Down 30.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Theravance Bio (TBPH)
The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study
Theravance Biopharma shares plummet 26% after its phase III CYPRESS study of ampreloxetine missed key endpoints, prompting the company to halt the program.
Theravance Biopharma shares plunge 26% after drug trial failure triggers strategic review
The company is working with Lazard on a potential sale after its lead drug candidate disappointed in a late-stage study Theravance Biopharma shares collapsed 26% in morning trading on Tuesday after the company said it was exploring a potential sale following the failure of its most advanced drug candidate in a late-stage clinical trial. The company said ampreloxetine, which was being tested in patients with multiple system atrophy, a rare and progressive neurological condition that can cause a dangerous fall in blood pressure upon standing, failed to demonstrate a meaningful improvement in symptoms compared with patients receiving a placebo.
Is the Options Market Predicting a Spike in Theravance Biopharma Stock?
Investors need to pay close attention to TBPH stock based on the movements in the options market lately.
